Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27754978 | 0.82 | MEN1 (0.47) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL6769554 | 0.79 | MEN1 (0.46) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL4983966 | 0.73 | NOTUM (0.47) | MEN1KMT2AALDH1A1MAPTTSHR | |
| SCHEMBL16353530 | 0.73 | SMN1; SMN2 (0.46) | MEN1KMT2AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1461151 | 0.72 | KMT2A (0.56) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL4685687 | 0.72 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1MAPTTSHR | |
| SCHEMBL9132803 | 0.72 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL3899031 | 0.69 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL14156263 | 0.69 | SMN1; SMN2 (0.46) | MEN1KMT2AALDH1A1MAPTPOLB | |
| SCHEMBL1408706 | 0.69 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912554-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-11-27 | — | — | EP | disclosed |
| US-6369060-B1 | CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY; 5-METHYL-6-TRIFLUOROMETHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY)-PYRIDIN-3-YL CARBAMOYL)INDOLINE AND 5-METHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY) -PYRIDAZIN-3-YLCARBAMOYL)-6-TRIFLUOROMETHYLINDOLINE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-09 | — | — | US | disclosed |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | disclosed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | disclosed |
| EP-0984956-A1 | INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-15 | — | — | EP | disclosed |
| CN-1230894-A | Containing 5HT2cAntagonists and D2Pharmaceutical compositions of antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | CN | disclosed |
| CN-1229408-A | Dihydroindole derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-09-22 | — | — | CN | disclosed |
| EP-0936924-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT 2C? ANTAGONIST AND A D 2? ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1999-08-25 | — | — | EP | disclosed |
| EP-0912554-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| EP-0912556-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998052943-A1 | INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998004289-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT2C ANTAGONIST AND A D2 ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997048699-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | HTR2C, HTR1A, HTR1D | MEN1 955/4885KMT2A 1090/4885ALDH1A1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.